Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies

Table 1

Patients, conditioning, and graft characteristics.

Patients, conditioning, and graft characteristics	ATG-F	Thymoglobulin
	Age at transplant, median (range, years)	59 (40–69)		51 (22–68)	0.49
Number of men, (%)	8 (53)	9 (60)	0.72
Group diagnosis, (%)
AML	6 (40)	6 (40)	1.00
MDS	2 (13)	0	0.46
CMML	0	3 (20)	0.23
MF	1 (7)	0	1.00
NHL/HD	5 (33)	4 (27)	0.69
MM	1 (7)	1 (7)	1.00
Undifferentiated AL	0	1 (7)	1.00
Complete remission at transplant, (%)	15 (100)	13 (87)	0.48
CMV serostatus donor/recipient, (%)
Positive recipient	11 (73)	12 (80)	0.67
Positive donor	7 (47)	8 (53)	0.72
Reason for RIC, (%)
Prior autologous SCT	8 (53)	8 (53)	1.00
Age	4 (27)	4 (27)	1.00
Other	3 (20)	3 (20)	1.00
Chemotherapy agents, (%)
Fludarabine-busulfan	13 (87)	12 (80)	0.67
Fludarabine-melphalan	2 (13)	3 (20)	1.00
Related donor, (%)	4 (27)	5 (33)	0.69
HLA-identical	4 (27)	5 (33)	0.69
Unrelated donor, (%)	11 (73)	10 (67)	0.69
0 mismatch	8 (53)	6 (40)	0.46
≥1 mismatch	3 (20)	4 (27)	0.67
Men donor, (%)	9 (60)	13 (87)	0.10
Sex mismatch in GvHD sense, (%)	4 (27)	1 (7)	0.33
Partial T cell depletion, (%)	7 (47)	9 (60)	0.46
T cell dose, median (range,  CD3/kg)	5 (0.35–130)	5 (0.35–100)	0.78
Blood group incompatibility, (%)
Major	4 (27)	4 (27)	1.00
Minor	4 (27)	5 (33)	0.91
Posttransplant immunosuppression, (%)	15 (100)	15 (100)	1.00